TRAVERE THERAPEUTICS, INC. Contract Liability (Deferred Revenue)
TRAVERE THERAPEUTICS, INC. (TVTX) had Contract Liability (Deferred Revenue) of $2.81 million as of 2024-12-31, per its 10-K filed 2025-02-21.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2025-02-21
- 2024-12-31: Contract with Customer, Liability, Current $2.81M.
- 2024-09-30: Contract with Customer, Liability, Current $3.80M.
- 2024-06-30: Contract with Customer, Liability, Current $5.38M.
- 2024-03-31: Contract with Customer, Liability, Current $6.46M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2024-12-31 | $2.81M 10-K · filed 2025-02-21 |
| 2024-09-30 | $3.80M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $5.38M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $6.46M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $7.10M 10-K · filed 2025-02-21 |
| 2023-09-30 | $8.96M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $10.24M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $10.97M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $11.98M 10-K · filed 2024-02-20 |
| 2022-09-30 | $11.38M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $12.50M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $14.23M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $16.27M 10-K · filed 2023-02-23 |
| 2021-09-30 | $16.07M 10-Q · filed 2021-10-29 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |